Prostaglandin analogs (PGA) have been the initial treatment of choice in many patients with glaucoma. However, there is an increasing awareness that non adherence and disruption of the ocular surface may limit PGA utility and tolerability respectively in some patients. In an eye with an open iridocorneal angle, these issues can potentially be addressed with the use of laser trabeculoplasty (LT). This therapy can achieve long-term intraocular pressure reduction following 1 to 2 treatment sessions without the ongoing need to apply medication (and preservatives) to the ocular surface. Whether PGAs or LT should be used in a given individual will also be influenced by other important factors including efficacy, response rate, tolerability, complications, cost and accessibility. This review examines these issues in relation to the initiation of primary therapy.
Wise JB, Witter SL. Argon laser therapy for open-angle glaucoma: A pilot study. Arch Ophthalmol 1979;97:319-22.
The AGIS investigators. The Advanced Glaucoma Intervention Study (AGIS): 1. Study design and methods and baseline characteristics of study patients. Contr Clin Trials 1994;15:299- 325.
Samples JR, Singh K, Lin SC, Francis BA, Hodapp E, Jampel HD, Smith SD. Laser trabeculoplasty for open-angle glaucoma: A report by the American Academy of Ophthalmology. Ophthalmology 2011 Nov;118(11):2296-302.
Nagar M, Ogunyomade A, O'Brart DPS, Howes F, Marshall J. A randomised, prospective study comparing selective laser trabeculoplasty with latanoprost for the control of intraocular pressure in ocular hypertension and open angle glaucoma. Br J Ophthalmol 2005;89:1413-17.
Katz LJ, Steinmann WC, Kabir A, Molineaux J, Wizov SS, Marcellino G. Selective laser trabeculoplasty versus medical therapy as initial treatment of glaucoma: A prospective, randomized trial. J Glaucoma 2011, DOI:10.1097/IJG.0b013e 318218287f.
McIlraith I, Strasfeld M, Colev G, Hutnik CM. Selective laser trabeculoplasty as initial and adjunctive treatment for open-angle glaucoma. J Glaucoma 2006;15:124-30.
Aptel F, Cucherat M, Denis P. Efficacy and tolerability of prostaglandin analogues. A meta-analysis of randomized controlled clinical trials. J Glaucoma 2008;17:667-73.
Camras CB, Hedman K. US latanoprost study group. Rate of response to latanoprost or timolol in patients with ocular hypertension or glaucoma. J Glaucoma 2003;12:466-69.
Friström B, Uusitalo H. A randomized, 36-month, postmarketing efficacy and tolerability study in Sweden and Finland of latanoprost versus non-prostaglandin therapy in patients with glaucoma or ocular hypertension. Acta Ophthalmologica 2010;88:37-43.
Shazly TA, Smith J, Latina MA. Long-term safety and efficacy of selective laser trabeculoplasty as primary therapy for the treatment of pseudoexfoliation glaucoma compared with primary open-angle glaucoma. Clinical Ophthalmology 2011;5:5-10.
Mao AJ, Pan XJ, McIlraith I, Strasfeld M, Colev G, Hutnik C. Development of a prediction rule to estimate the probability of acceptable intraocular pressure reduction after selective laser trabeculoplasty in open-angle glaucoma and ocular hypertension. J Glaucoma 2008;17:449-54.
Ayala M, Chen E. Predictive factors of success in selective laser trabeculoplasty (SLT) treatment. Clin Ophthalmol 2011;5: 573-76.
El Mallah MK, Walsh MM, Stinnett SS, Asrani SG. Selective laser trabeculoplasty reduces mean IOP and IOP variation in normal tension glaucoma patients. Clinical Ophthalmology 2010;4:889-93.
Cheng JW, Cai JP, Wei RL. Meta-analysis of medical intervention for normal tension glaucoma. Ophthalmology 2009;116:1243-49.
Tsuda M, Ando A, Matsuyama K, Otsuji T, Fukui C, Maenishi N, et al. Intraocular pressure (IOP) reduction by latanoprost in Japanese normal tension glaucoma patients over a five-year period stratified by presenting IOP. J Ocul Pharmacol Ther 2009;25:441-45.
Dreer LE, Girkin C, Mansberger SL. Determinants of medication adherence to topical glaucoma therapy. J Glaucoma 2012;21:234-40.
Murakami Y, Lee BW, Duncan M, Kao A, Huang JY, Singh K, Lin SC. Racial and ethnic disparities in adherence to glaucoma follow-up visits in a county hospital population. Arch Ophthalmol 2011 Jul;129(7):872-78.
Glanz K, Beck AD, Bundy L, Primo S, Lynn MJ, Cleveland J, et al. Impact of a health communication intervention to improve glaucoma treatment adherence: Results of the interactive study to increase glaucoma adherence to treatment trial results of the I-sight trial. Arch Ophthalmol 2012;11:1-7.
Wilensky J, Fiscella RG, Carlson AM, Morris LS, Walt J. Measurement of persistence and adherence to regimens of IOPlowering glaucoma medications using pharmacy claims data. Am J Ophthalmol 2006;141:S28-33.
Caprioli J, Varma R. Intraocular pressure: Modulation as treatment for glaucoma. Am J Ophthalmol 2011;152:340-44.
Prasad N, Murthy S, Dagianis JJ, Latina MA. A comparison of the intervisit intraocular pressure fluctuation after 180 and 360 degrees of selective laser trabeculoplasty as a primary therapy in primary open angle glaucoma and ocular hypertension. J Glaucoma 2009;18:157-60.
Kóthy P, Tóth M, Holló G. Influence of selective laser trabeculoplasty on 24-hour diurnal intraocular pressure fluctuation in primary open-angle glaucoma: A pilot study. Ophthalmic Surg Lasers Imaging 2010;41:342-47.
Varma R, Lie-Ju H, Grunden JW, Bean GW, Sultan MB. Assessing the efficacy of latanoprost vs timolol using an alternate efficacy parameter: The intervisit intraocular pressure range. Am J Ophthalmol 2009;148:221-26.
Nagar M, Luhishi E, Shah N. Intraocular pressure control and fluctuation: The effect of treatment with selective laser trabeculoplasty. Br J Ophthalmol 2009;93:497-501.
Uusitalo H, Pillunat LE, Ropo A. Efficacy and safety of tafloprost 0.0015% versus latanoprost 0.005% eye drops in openangle glaucoma and ocular hypertension: 24-month results of a randomized, double masked phase III study. Acta Ophthalmologica 2010;88:12-19.
Katz G, Springs Cl, Craven ER, Montecchi-Palmer M. Ocular surface disease in patients with glaucoma or ocular hypertension treated with BAK-preserved latanoprost or BAK-free travoprost. Clin Ophthalmol 2010;4:1253-61.
Skalicky SE, Goldberg I, McCluskey P. Ocular surface disease and quality of life in patients with glaucoma. Am J Ophthalmol 2012;153:1-9.
Latina MA, Sibayan SA, Shin DH, et al. Q-switched 532 nm Nd:YAG laser trabeculoplasty (selective laser trabeculoplasty): A multicenter, pilot, clinical study. Ophthalmology 1998;105:2082-90.
Damji KF, Shah KC, Rock WJ, et al. Selective laser trabeculoplasty vs argon laser trabeculoplasty: A prospective randomised clinical trial. Br J Ophthalmol 1999;83:718-22.
Seider MI, Keenan JD, Han Y. Cost of selective laser trabeculoplasty vs topical medications for glaucoma Arch Ophthalmol 2012;130:529-30.
Stein JD, Kim DD, Peck WW, Giannetti SM, Hutton DW. Costeffectiveness of medications compared with laser trabeculoplasty in patients with newly diagnosed open-angle glaucoma. Arch Ophthalmol 2012;130:497-505.
